Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth.

Saved in:
Bibliographic Details
Title: Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth.
Authors: Kenny HA; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Ip CKM; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Kelliher L; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Samantaray T; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Kordylewicz K; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Hoffmann R; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Rauch S; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Malacrida B; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Skingsley SLP; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Balkwill FR; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Battistini C; Unit of Gynecological Oncology Research, European Institute of Oncology IRCCS, Milan, Italy., Cavallaro U; Unit of Gynecological Oncology Research, European Institute of Oncology IRCCS, Milan, Italy., Wiedemeyer WR; AbbVie Inc., North Chicago, Illinois., Lengyel E; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2025 Aug 01; Vol. 24 (8), pp. 1252-1264.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1538-8514
DOI:10.1158/1535-7163.MCT-23-0863